| Bioactivity | F 16915, a Docosahexaenoic Acid (DHA, HY-B2167) derivative, is a potent pro-drug of DHA. F 16915 can prevent heart failure-induced atrial fibrillation[1]. |
| In Vivo | F 16915 (100 mg/kg; daily oral gavage for 2 months) reduces marked dilation of the left atrial (LA) cavity and the steep decline of left ventricular (LV) contractile function occurring 2 months after infarction and reperfusion in rats[1].F 16915 (1-5 g/day for 4 weeks) significantly reduces the infarct size and prevents the left ventricular free wall thinning[1]. Animal Model: |
| Name | F 16915 |
| CAS | 92510-91-3 |
| Formula | C28H37NO2 |
| Molar Mass | 419.60 |
| Appearance | Oil |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Le Grand B, et al. F 16915 prevents heart failure-induced atrial fibrillation: a promising new drug as upstream therapy. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):667-77. |